To observe clinical effects of Ligustrazine Injection and Shengmai Injection combined with western medicine in the treatment of patients with chronic pulmonary heart disease. Methods: A total of 134 patients were randomized into observation and control groups, 68 cases, 66 cases respectively. Control group was treated with conventional western medicine, the observation Group were treated with ligustrazine Injection and Shengmai Injection in addition. Results: Three patients in observation Group recovered, curative rate=4.41%, 31 patients improved, effective rate= 45.59 %, responded rate= 50%, total effective rate=92.65 %. 1 patients in control Group recovered, curative rate =1.51%, 17 patients improved, effective rate= 25.76 %, responded rate=27.33 %, total effective rate= 83.33 %. Recovery rates were not significantly different between 2 groups (P>0.05), responded rate and total effective rates were significantly different (P<0.05). Observation group was significantly better at reducing cough, difficult breathing, heady sound, daily sputum volume compared with the control group (P<0.05). Both groups improved significantly after treatment in terms of heart functions, right atrial pressure (RAP), right ventricular pressure (RVP) and mean pulmonary arterial pressure (mPAP). RVP and mPAP improvements in observation group were significantly different than those of the control group (P<0.05) No significant adverse reaction of Ligustrazine and Shengmai Injection was reported. Conclusion: Ligustrazine hydrochloride Injection and Shengmai Injection combined with western medicine is safe and effective treatment for chronic pulmonary heart disease, better than using western medicine alone.